Research Article |
Corresponding author: Olena Popazova ( popazova.ea@gmail.com ) Academic editor: Georgi Momekov
© 2022 Igor Belenichev, Lyudmyla Kucherenko, Sergii Pavlov, Nina Bukhtiyarova, Olena Popazova, Natalia Derevianko, Ganna Nimenko.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Belenichev I, Kucherenko L, Pavlov S, Bukhtiyarova N, Popazova O, Derevianko N, Nimenko G (2022) Therapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline). Pharmacia 69(2): 509-516. https://doi.org/10.3897/pharmacia.69.e82596
|
COVID-19 leads to disruption of the blood coagulation system, to thrombosis, hypercoagulability, as a result, to an increased risk of strokes and heart attacks. During COVID-19, endothelial dysfunction develops associated with NO deficiency with decrease in the level of SH compounds. Tiazotic acid (Thiotriazoline) has immunomodulatory, anti-inflammatory, antioxidant, anti-ischemic, cardio- and endothelioprotective, antiplatelet, hepatoprotective activity. Our studies conducted at the National Research Medical Center “University Clinic of ZSMU” with the participation of 57 patients (from 30 to 65 years old) with post-COVID syndrome, who received thiotriazol with basic therapy in either tablets (200 mg each) or suppositories Dalmaxin (0.2 g each) twice a day for 30 days. Inclusion criteria for the study were a positive PCR test for COVID-19; if the PCR test was negative, then the presence of IgM COVID-19 or IgG COVID-19 (with radiologically confirmed pneumonia). The following biochemical parameters were studied: C-reactive protein - by immunoturbodimetric method; D-dimer - by enzyme immunoassay; ferritin - by immunochemiluminescent method; endothelial NO-synthase (eNOS) - by ELISA method; alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), total bilirubin; international normalized ratio (INR) and determination of platelet aggregation. During treatment with thiotriazoline, significant increase in the eNOS content was recorded, which indicated the presence of endothelioprotective activity of the drug. Thiotriazoline significantly reduced the level of D-dimer in the blood of patients, and also led to the normalization of INR. The established effects testified to the presence of antiplatelet and fibrinolytic action of thiotriazoline and its ability to reduce the risks of heart attacks and strokes in post-COVID syndrome. Thiotriazoline led to an objective improvement in general clinical parameters in patients with post-COVID syndrome, complaints of palpitations disappeared, blood pressure stabilized.
Tiazotic acid (Thiotriazoline), post-COVID syndrome, antiplatelet, anticoagulant, endothelioprotective and hepatoprotective action
Relevance. Coronavirus disease is associated with severe inflammation and cytokine storms (Zhao et al. 2019;
The very interesting effects of thiotriazoline include its protective effect on the vascular endothelium, which is of great importance in COVID-19, since endothelial dysfunction inevitably develops in this pathology. It is noted that the formation of endothelial dysfunction in COVID-19 occurs more rapidly in elderly patients taking ACE inhibitors (
Drug therapy for COVID-19 is aggressive, has a number of serious adverse reactions from the liver and a number of contraindications (patients with liver failure who have had hepatitis, elderly patients). In parallel with the use of the drug in cardiology, tiazotic acid is used in the treatment of diseases of the liver and other internal organs, given the high hepatoprotective properties. The drug prevents the destruction of hepatocytes, reduces the degree of fatty infiltration and the spread of centrilobular necrosis of the liver, promotes reparative regeneration of hepatocytes, normalizes their protein, carbohydrate, lipid and pigment metabolism. Increases the rate of synthesis and excretion of bile, normalizes its chemical composition (
The above-mentioned hepatoprotective properties of thiotriazoline can be an essential component of the complex therapy of post-COVID syndrome, given the pronounced hepatotoxicity of drugs used for the basic therapy of coronavirus infection.
Thus, thiotriazoline is a drug with immunomodulatory, antiinflammatory, antioxidant, cardioprotective and hepatoprotective properties; with extensive experience in clinical practice; the safety profile has been carefully studied, which is the basis for its use for the treatment (as part of combination therapy) of patients with post-COVID syndrome. The above is the basis for conducting clinical trials of thiotriazoline for the purpose of its use in the complex therapy of post-COVID syndrome.
The aim of the study. Evaluation of the complex therapeutic effect of thiotriazoline (anticoagulant, antiplatelet, endothelioprotective, hepatoprotective action) in patients with post-COVID syndrome in comparison with basic therapy.
The studies were carried out on the basis of the ZSMU University Clinic. The studies involved 15 relatively healthy volunteers and 57 patients aged 30 to 65 with post-COVID syndrome. Of these, 20 patients received basic therapy (antibiotics, anticoagulants, acetylsalicylic acid), and 37 patients additionally received thiotriazoline during basic therapy (28 patients received thiotriazoline in the form of tablets (Corporation Arterium, Ukraine (200 mg each), 9 patients - in the form of suppositories Dalmaxin (MobilMedical, Ukraine) 0.2 g each (active ingredient - thiotriazoline) twice a day for 30 days. The inclusion criteria for the study were a positive PCR test for COVID-19; if the PCR test was negative, then the presence of IgM COVID-19 or IgG COVID-19 (with radiologically confirmed pneumonia). The presence of pneumonia was confirmed by computer or X-ray examination of the chest cavity. The level of lung damage is up to 45%. Patients had the following comorbidities: diabetes mellitus in the compensation stage, arterial hypertension, coronary heart disease without heart failure. The following biochemical parameters were studied: C-reactive protein - immunoturbodimetric method (Cormay kit, biochemical analyzer ACCENT-200, Poland); D-dimer - enzyme immunoassay (kit manufactured by “Vector-Best”, enzyme immunoassay analyzer - “Immunochem2200”, USA); ferritin - immunochemiluminescent method (kit manufactured by Siemens, analyzer - Immulate 1000, UK); endothelial NO synthase (eNOS) – enzyme immunoassay, kit manufactured by Cloud-Clone Corporation, USA (enzymatic immunoassay analyzer – Immunochem-2200, USA). To establish the hepatoprotective effect of thiotriazoline in post-COVID syndrome, a biochemical determination of hepatic enzymes was carried out: alanine aminotransferase (AlAT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), the level of total bilirubin (diagnostic kits; a thymol test was performed by the turbodynamic method (RPA “Filisit-Diagnostics”). Also, the international normalized ratio (INR) was determined - the coagulometric method (set manufactured by Diagon, Austria, device - coagulometer CoagChrom 3003, Poland). Simultaneously with biochemical studies, platelet aggregation is determined to assess the hemostatic function of platelets. Platelet aggregation activity was studied by the turbidimetric method (optical aggregometry) using a Solar AP 2110 aggregometer (Republic of Belarus).
Investigation of the level of platelet aggregation activity - with the introduction of the inducer of ADP aggregation (5.0 μM). Material for research: platelet-rich citrate plasma. Two weeks before the study, they stopped taking drugs that affect platelet aggregation. Whole blood was collected in a plastic tube with 3.2% (0.109 M) or 3.8% (0.129 M) sodium citrate in a ratio of 9:1 or in a vacuum blood collection system with 3.2% (0.109 M) sodium citrate. Immediately after blood sampling, the contents of the tube were gently mixed by inverting at least 5 times without foaming. Within 45 minutes, the tube was delivered to the laboratory and centrifuged. Whole blood sample centrifugation was performed at room temperature (18–25 °C) for 5–7 minutes at 1000 rpm. After centrifugation was completed, 1 ml of TRP was immediately taken into a clean tube for further study. Obtaining platelet-poor plasma (PPP) is used as a blank sample (reference point). To obtain platelet-poor plasma, a whole blood sample was centrifuged at room temperature (18–25 °C) for 15 minutes at 3000 rpm. After centrifugation was completed, 1 ml of PRP was taken into a clean plastic tube. Blood sampling was performed only in vacuum systems or plastic tubes with 3.8% sodium citrate. Before the analysis, a preliminary count of cells in plasma was carried out on a hematological analyzer or a microscopic method, and in accordance with the results obtained, platelet-rich plasma was diluted with platelet-poor plasma (from the same patient) so that the total number of platelets in the mixture was 200–300×109/l. An ADP solution with a concentration of 5.0 μM was used as an aggregation activator. To prepare a working solution, 4.7 mg of ADP was added to 20 ml of saline, then 1 ml of the resulting solution was added to 9 ml of saline. The results obtained were measured by the percentage of light absorption. The results of the study were calculated using the standard statistical package “STATISTICA for Windows 6.0” (StatSoftInc., No. AXXR712D833214FAN5), as well as “SPSS 16.0”, “Microsoft Office Excell 2003”. Distribution normality was assessed using the Shapiro-Wilk test. Data were presented by mean. The significance of negativity between the mean values was determined by Student’s t-test (in the case of a normal distribution). In the case of a distribution that is negative from normal, or analysis of ordinal variables, the U Mann-Whitney test was used. To compare independent variables in more than two samples, analysis of variance (ANOVA) with a normal distribution or the Kruskal-Wallis test for a distribution that differed from normal in the negative direction was used. For all analyzes, negatives р<0.05 (95%) were considered statistically significant.
Upon admission, all patients complained of severe weakness, increased fatigue, palpitations, fever from 37.2 to 38.3 °C. The level of lung damage is up to 45%. Complaints about the lack of smell and taste had 51% of patients, cough - 49.1%, shortness of breath - 43%, diarrhea and abdominal pain - an average of 24.5% (Table
Complaints/indicators | On admission n=57 | Group 1 - basic therapy (control) after treatment n=20 | Group 2 - basic therapy + thiotriazoline (after treatment) (n=37; 28 patients received tablets, 9 received suppositories) |
---|---|---|---|
Weakness | 55 | 17 | 2 |
Body temperature from 37.2° to 38.3° | 55 | – | – |
No sense of smell or taste | 29 | 7 | 3 |
Dyspnea | 25 | 11 | 2 |
Cough | 28 | 8 | – |
Heartbeat | 55 | 16 | 3 |
Rhythm disturbance | – | – | – |
Diarrhea | 14 | 2 | – |
Abdominal pain | 14 | 2 | – |
Fatigue | 54 | 14 | 2 |
Saturation at the level of 98–99% | – | 9 | 35 |
The conducted biochemical and coagulometric studies showed that in patients with post-COVID syndrome, eNOS expression derivation was established with an increase in the concentration of ferritin and C-reactive protein in relation to relatively healthy ones. Studies have shown that in patients with post-COVID syndrome during treatment with basic therapy (antibiotics, anticoagulants, acetylsalicylic acid), compared with relatively healthy patients, an increased concentration of C-reactive protein and ferritin was observed (Table
Biochemical parameters of blood plasma and INR in patients with post-COVID syndrome (30 days from the start of treatment).
Groups of patients | C-reactive protein, mg / l | Feritin, ng / ml | D-dimer DDU | INR |
---|---|---|---|---|
Relatively healthy (п=15) | 9,1±0,8 | 330±10,1 | 130,2±14,6 | 0,92±0,04 |
On admission n=57 | 21,4±2,8 | 478,3±7,6 | 190,3±6,1 | 0,44±0,03 |
Post-COVID syndrome + basic therapy (n=20) | 20,4±1,21 | 409,2±6,5 | 155±10,2 | 0,58±0,05 |
Post-COVID syndrome + basic therapy + thiotriazoline (n=37; 28 patients received tablets, 9 received suppositories) | 19,9±1,31 | 388±7,3*1 | 132±6,5*1 | 0,89±0,03*1 |
Concentration of eNOS in the blood plasma of patients with post-COVID syndrome (30 days from the start of treatment).
Groups of patients | eNOS, pg / ml |
---|---|
Relatively healthy (n=15) | 57,8±4,3 |
On admission (n=57) | 24,1±5,2 |
Post-COVID syndrome + basic therapy (n=20) | 31,4±4,7 |
Post-COVID syndrome + basic therapy + thiotriazoline (n=37; 28 patients received tablets, 9 received suppositories) | 54,1±4,7*1 |
When determining the aggregation activity of platelets, it was found that in patients with post-COVID syndrome during treatment with basic therapy, compared with healthy patients, an increase in platelet aggregation activity was observed. The percentage of light absorption averaged 99.4% versus 60% of relatively healthy patients (Table
Hemostasiogram of patients with post-COVID syndrome (30 days from the start of treatment) (%).
Groups of patients | Platelet aggregation with ADP, % | Speed at 30 seconds, % | Number of platelets, 109/l |
---|---|---|---|
Relatively healthy (п=15) | 60±10,4 | 70±15,2 | 311±31,4 |
Post-COVID syndrome + basic therapy (п=20) | 100,4±7,3 | 161,4±8,6 | 380±53,6 |
Post-COVID syndrome + basic therapy + thiotriazoline (n=37; 28 patients received tablets, 9 received suppositories) | 68,5±4,8* | 74,6±7* | 338±26,1 |
Platelet aggregation activity. А. Relatively healthy patients. Aggregation response in the reference interval. Irreversible aggregation, percentage light transmission 60%; B. patients with post-COVID syndrome during treatment with basic therapy. Aggregation response in the reference interval. Irreversible aggregation, percentage light transmission 93%; С. Patients with post-COVID syndrome during treatment with basic therapy and thiotriazoline. Aggregation response in the reference interval. Irreversible aggregation, percentage light transmission 75%.
We have obtained data on the protective effect of thiotriazoline on the vascular endothelium, which is of great importance in COVID-19, since endothelial dysfunction inevitably develops in this pathology. It has been noted that the formation of endothelial dysfunction in COVID-19 occurs more rapidly in elderly patients taking ACE inhibitors. Endothelial dysfunction is a predictor of such formidable diseases as strokes and myocardial infarctions. It is well known that NO is an unstable, short-lived radical, and for its stabilization and subsequent transportation, mechanisms such as interaction with thiol-containing low molecular weight compounds (glutathione, cysteine, methionine) and reproduction of stable S-nitrosol complexes are provided. Under conditions of deficiency of thiol compounds in COVID-19, NO transport is disrupted, as it is attacked by such ROS as superoxide radical and hydroxyl radical with transformation into a cytotoxic product, peroxynitrite (
One of the important components of the post-COVID syndrome is the development of adverse side effects of drugs used to treat coronavirus disease, namely, violations of the hepatobiliary system and the protective function of the liver. In patients, an increase in liver enzymes in the blood plasma, an increase in the content of bilirubin was observed. In 54 out of 57 patients during hospitalization, asthenovegetative, cholestatic, pain syndrome in the epigastrium and right hypochondrium was recorded.
The introduction of thiotriazoline into basic therapy in the form of tablets (200 mg twice a day) or suppositories (200 mg twice a day) for 30 days led to a decrease in the manifestation of the cytolytic syndrome, which was manifested in a decrease in ALT and AST by 55.7%. and 66.7% compared with the group of patients at admission and 48.7% and 60.6%, respectively, compared with the group of patients receiving basic therapy. It is important to note that in the group of patients who received basic therapy, the AST value remained elevated (Table
Biochemical parameters of the liver tissue of patients with post-COVID syndrome (30 days from the start of treatment).
Groups of patients | ALAT U / l | АСТ, U / l | GGT, U / l | Thymol test, Sh | Total bilirubin, µmol / l |
---|---|---|---|---|---|
Relatively healthy (п=15) | 18,4±,1,5 | 9,2±0,6 | 24,5±2,5 | 1,2±0,07 | 12,8±1,5 |
On admission (n=57) | 64,2±3,8 | 52,1±2,7 | 82,4±3,4 | 11,4±2,2 | 22,7±1,8 |
Post-COVID syndrome + basic therapy (n=20) | 55,4±3,7* | 44,2±1,1* | 78,4±2,3 | 6,7±0,5* | 20,4±1,8 |
Post-COVID syndrome + basic therapy + thiotriazoline (n=37; 28 patients received tablets, 9 received suppositories) | 28,4±2,8*1 | 17,4±1,2*1 | 26,4±1,71 | 0,7±0,05*1 | 11,3±0,9*1 |
According to previous studies, the mechanism of the hepatoprotective action of thiotriazoline lies in its antioxidant, membrane-protective and mitoprotective activity. Thiotriazoline is able to protect the enzymes of the pentose phosphate shunt, the tricarboxylic acid cycle in hepatocytes from their oxidative damage, which ensures a sufficiently high level of energy and plastic processes in the liver tissue (
The obtained clinical and biochemical results demonstrate the hepatoprotective effect of thiotriazoline. And given a number of serious side effects of basic drugs (antibiotics, antiviral agents, NSAID antiplatelet agents) aimed at disrupting the subtle links of the metabolism of cardiomyocytes, endotheliocytes, hepatocytes, etc., the appointment of thiotriazoline in the complex therapy of post-COVID syndrome can increase the safety of the proposed drug treatment.
Thus, the introduction of the drug tiazotic acid (thiotriazoline) in the form of tablets (200 mg twice a day) or suppositories Dalmaxin (200 mg twice a day) into the complex basic therapy of the post-COVID syndrome for 30 days led to a significant increase in the basic endothelioprotective anticoagulant therapy, contributed to the prevention of thrombus formation while improving the condition of the myocardium and vascular endothelium, and also reduced disorders of the hepatobiliary system caused by both the disease itself and side effects of basic therapy.